Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F J Cohen

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Cancer|May 17, 2000
Effects of high dose raloxifene in selected patients with advanced breast carcinomaW Gradishar, J Glusman, Y Lu, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|May 5, 1999
The absence of 150-kDa insulin-like growth factor complexes in fetal rat serum is not due to a lack of functional acid-labile subunitC Y Lee, F J Cohen, H B Wu, et al.
Molecular Endocrinology (Baltimore, Md.)|June 1, 1997
Growth hormone stimulates transcription of the gene encoding the acid-labile subunit (ALS) of the circulating insulin-like growth factor-binding protein complex and ALS promoter activity in rat liverG T Ooi, F J Cohen, L Y Tseng, et al.
Progress in Growth Factor Research|January 1, 1995
Structure and regulation of the ALS geneG T Ooi, F J Cohen, S Hsieh, et al.
Menopause (New York, N.Y.)|September 16, 1999
Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal womenG C Davies, W J Huster, W Shen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 6, 2001
Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patientsM Dowsett, N J Bundred, A Decensi, et al.
Archives of Internal Medicine|December 9, 2000
Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trialsC C Johnston, N H Bjarnason, F J Cohen, et al.
JAMA|October 12, 1999
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) InvestigatorsB Ettinger, D M Black, B H Mitlak, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Cancer|May 17, 2000
Effects of high dose raloxifene in selected patients with advanced breast carcinomaW Gradishar, J Glusman, Y Lu, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|May 5, 1999
The absence of 150-kDa insulin-like growth factor complexes in fetal rat serum is not due to a lack of functional acid-labile subunitC Y Lee, F J Cohen, H B Wu, et al.
Molecular Endocrinology (Baltimore, Md.)|June 1, 1997
Growth hormone stimulates transcription of the gene encoding the acid-labile subunit (ALS) of the circulating insulin-like growth factor-binding protein complex and ALS promoter activity in rat liverG T Ooi, F J Cohen, L Y Tseng, et al.
Progress in Growth Factor Research|January 1, 1995
Structure and regulation of the ALS geneG T Ooi, F J Cohen, S Hsieh, et al.
Menopause (New York, N.Y.)|September 16, 1999
Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal womenG C Davies, W J Huster, W Shen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 6, 2001
Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patientsM Dowsett, N J Bundred, A Decensi, et al.
Archives of Internal Medicine|December 9, 2000
Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trialsC C Johnston, N H Bjarnason, F J Cohen, et al.
JAMA|October 12, 1999
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) InvestigatorsB Ettinger, D M Black, B H Mitlak, et al.
Pageof 2